First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

Lemery et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69442f9a0bf1812605412fc1 — DOI: https://doi.org/10.1056/nejmp1709968

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Microsatellite Instability as a Biomarker for PD-1 Blockade· 2016 · 982 citations
2. Classification and characterization of microsatellite instability across 18 cancer types· 2016 · 1,012 citations
3. Mismatch Repair Status and <i>BRAF</i> Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies· 2014 · 735 citations
4. Abstract PD2-08: Neratinib + fulvestrant in <i>ERBB2</i>-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial· 2017 · 18 citations
5. Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer· 2015 · 689 citations